NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has entered into a research collaboration with Ameritox to evaluate the use of Agilent's RapidFire platform in medication monitoring.

The RapidFire system is a high-throughput mass spectrometry platform that was developed for drug screening by Biocius, a spinout of BioTrove that Agilent acquired two years ago. The RapidFire 360 system was launched in May 2010 for the high-throughput screening of in vitro ADME assays.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.